Peter Attia· MD
so there's one called CT gf which if you make an antibody against that you have efficacy in a rare lung disease that's profile that we now know is driven by senescence that's not a marketed drug yet
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so there's one called CT gf which if you make an antibody against that you have efficacy in a rare lung disease that's profile that we now know is driven by senescence that's not a marketed drug yet
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there's also some SAS factors that have been clinically validated so there's one called CT gf which if you make an antibody against that you have efficacy in a rare lung disease that's profile that we now know is driven by senescence